Literature DB >> 15066936

Loss of antigenicity in stored sections of breast cancer tissue microarrays.

Jennifer H Fergenbaum1, Montserrat Garcia-Closas, Stephen M Hewitt, Jolanta Lissowska, Lori C Sakoda, Mark E Sherman.   

Abstract

Immunohistochemical characterization of tumor tissues in epidemiological studies is a promising approach to identify breast cancer subtypes with distinct etiology. The recent development of the tissue microarray (TMA) technique allows for standardized, rapid, and cost-effective immunohistochemical characterization of many cases, which is critical in epidemiological studies. Sectioning paraffin blocks at different times results in loss of material, which can be reduced by preparing many sections each time a block is cut. However, data suggest that staining intensity declines in whole sections prepared from conventional paraffin blocks with storage time, resulting in false-negative results. This problem would be accentuated in TMAs because of the limited tissue representation of each case. To evaluate this concern, we prepared a single TMA block from 125 invasive breast carcinomas collected in a population-based case-control study conducted in Poland and compared estrogen receptor (ER-alpha), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in sections cut and stored for 6 months at room temperature with sections cut from the same TMA block and stained on the same day. Percentage of positive cases for stored versus fresh sections was similar for ER (59.0%) but significantly higher in fresh sections for PR (56.3% versus 64.1%, P = 0.01) and HER2 (45.5% versus 64.4%, P < 0.001). Among cases positive in both stored and fresh sections, the median percentage of immunoreactive cells was significantly reduced and the staining intensity was consistently lower in stored compared with fresh sections. We conclude that loss of immunoreactivity is an important problem in TMAs of breast cancer. Improved methods for sectioning TMAs and storing tissue sections aimed at reducing loss of immunoreactivity are critical for the use of TMAs in epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066936

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

1.  Effects of long-term storage on the detection of proteins, DNA, and mRNA in tissue microarray slides.

Authors:  Christina Karlsson; Mats G Karlsson
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

2.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

3.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

4.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

Review 5.  The Henry Ford production system: LEAN process redesign improves service in the molecular diagnostic laboratory: a paper from the 2008 William Beaumont hospital symposium on molecular pathology.

Authors:  Milena Cankovic; Ruan C Varney; Lisa Whiteley; Ron Brown; Rita D'Angelo; Dhananjay Chitale; Richard J Zarbo
Journal:  J Mol Diagn       Date:  2009-08-06       Impact factor: 5.568

6.  Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Authors:  David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; Anthony M Magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann Thor; Donald A Berry
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

7.  Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections.

Authors:  Ran Xie; Joon-Yong Chung; Kris Ylaya; Reginald L Williams; Natalie Guerrero; Nathan Nakatsuka; Cortessia Badie; Stephen M Hewitt
Journal:  J Histochem Cytochem       Date:  2011-02-10       Impact factor: 2.479

8.  A 'waterfall' transfer-based workflow for improved quality of tissue microarray construction and processing in breast cancer research.

Authors:  M Oberländer; H Alkemade; S Bünger; F Ernst; C Thorns; T Braunschweig; J K Habermann
Journal:  Pathol Oncol Res       Date:  2014-03-07       Impact factor: 3.201

9.  High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.

Authors:  Yanan Kong; Shuqin Dai; Xinhua Xie; Xiangsheng Xiao; Ning Lv; Jiaoli Guo; Laisheng Li; Weihua Jia; Yin Zhang; Wanli Liu; Weidong Wei; Xiaoming Xie
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-25       Impact factor: 4.553

10.  Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.

Authors:  Mia M Gaudet; Michael F Press; Robert W Haile; Charles F Lynch; Sally L Glaser; Joellen Schildkraut; Marilie D Gammon; W Douglas Thompson; Jonine L Bernstein
Journal:  Breast Cancer Res Treat       Date:  2011-06-11       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.